Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial

Jorinde A W Polderman, Peter L Houweling, Markus W Hollmann, J Hans DeVries, Benedikt Preckel, Jeroen Hermanides, Jorinde A W Polderman, Peter L Houweling, Markus W Hollmann, J Hans DeVries, Benedikt Preckel, Jeroen Hermanides

Abstract

Background: Diabetes mellitus (DM) is associated with poor outcome after surgery. The prevalence of DM in hospitalised patients is up to 40%, meaning that the anaesthesiologist will encounter a patient with DM in the operating room on a daily basis. Despite an abundance of published glucose lowering protocols and the known negative outcomes associated with perioperative hyperglycaemia in DM, there is no evidence regarding the optimal intraoperative glucose lowering treatment. In addition, protocol adherence is usually low and protocol targets are not simply met. Recently, incretins have been introduced to lower blood glucose. The main hormone of the incretin system is glucagon-like peptide-1 (GLP-1). GLP-1 increases insulin and decreases glucagon secretion in a glucose-dependent manner, resulting in glucose lowering action with a low incidence of hypoglycaemia. We set out to determine the optimal intraoperative treatment algorithm to lower glucose in patients with DM type 2 undergoing non-cardiac surgery, comparing intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GPL-1 (liragludite, LG) treatment.

Methods/design: This is a multicentre randomised open label trial in patients with DM type 2 undergoing non-cardiac surgery. Patients are randomly assigned to one of three study arms; intraoperative glucose-insulin-potassium infusion (GIK), intraoperative sliding-scale insulin boluses (BR) or GPL-1 pre-treatment with liraglutide (LG). Capillary glucose will be measured every hour. If necessary, in all study arms glucose will be adjusted with an intravenous bolus of insulin. Researchers, care givers and patients will not be blinded for the assigned treatment. The main outcome measure is the difference in median glucose between the three study arms at 1 hour postoperatively. We will include 315 patients, which gives us a 90% power to detect a 1 mmol l(-1) difference in glucose between the study arms.

Discussion: The PILGRIM trial started in January 2014 and will provide relevant information on the perioperative use of GLP-1 agonists and the optimal intraoperative treatment algorithm in patients with diabetes mellitus type 2.

Trial registration: ClinicalTrials.gov, NCT02036372.

Keywords: Diabetes mellitus type 2; GLP-1 agonist; Perioperative management.

Figures

Figure 1
Figure 1
Consort flow diagram of PILGRIM trial.

References

    1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–1431. doi: 10.2337/diacare.21.9.1414.
    1. Akhtar S, Barash PG, Inzucchi SE. Scientific principles and clinical implications of perioperative glucose regulation and control. Anesth Analg. 2010;110(2):478–497. doi: 10.1213/ANE.0b013e3181c6be63.
    1. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE. Unrecognized diabetes among hospitalized patients. Diabetes Care. 1998;21(2):246–249. doi: 10.2337/diacare.21.2.246.
    1. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE, American Association of Clinical Endocrinologists, American Diabetes Association American association of clinical endocrinologists and American diabetes association consensus statement on inpatient glycemic control. Endocr Practice Off J Am College Endocrinol Am Assoc Clinical Endocrinol. 2009;15(4):353–369.
    1. Robertshaw HJ, Hall GM. Diabetes mellitus: anaesthetic management. Anaesthesia. 2006;61(12):1187–1190. doi: 10.1111/j.1365-2044.2006.04834.x.
    1. Blondet JJ, Beilman GJ. Glycemic control and prevention of perioperative infection. Curr Opin Crit Care. 2007;13(4):421–427. doi: 10.1097/MCC.0b013e32826388a1.
    1. Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, Hudson M, Mendoza J, Johnson R, Lin E, Umpierrez GE. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care. 2010;33(8):1783–1788. doi: 10.2337/dc10-0304.
    1. Pomposelli JJ, Baxter JK, 3rd, Babineau TJ, Pomfret EA, Driscoll DF, Forse RA, Bistrian BR. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr. 1998;22(2):77–81. doi: 10.1177/014860719802200277.
    1. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, Hirsch IB, American Diabetes Association Diabetes in Hospitals Writing C Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553–591. doi: 10.2337/diacare.27.2.553.
    1. Eshuis WJ, Hermanides J, van Dalen JW, van Samkar G, Busch OR, van Gulik TM, DeVries JH, Hoekstra JB, Gouma DJ. Early postoperative hyperglycemia is associated with postoperative complications after pancreatoduodenectomy. Ann Surg. 2011;253(4):739–744. doi: 10.1097/SLA.0b013e31820b4bfc.
    1. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA J Am Med Assoc. 2003;290(15):2041–2047. doi: 10.1001/jama.290.15.2041.
    1. Ponce BA, Menendez ME, Oladeji LO, Soldado F. Diabetes as a risk factor for poorer early postoperative outcomes after shoulder arthroplasty. J Shoulder Elbow Surgery/Am Shoulder Elbow Surg [et al] 2014;23(5):671–678. doi: 10.1016/j.jse.2014.01.046.
    1. Smiley DD, Umpierrez GE. Perioperative glucose control in the diabetic or nondiabetic patient. South Med J. 2006;99(6):580–589. doi: 10.1097/01.smj.0000209366.91803.99.
    1. Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O'Brien PC, Johnson MG, Williams AR, Cutshall SM, Mundy LM, Rizza RA, McMahon MM. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med. 2007;146(4):233–243. doi: 10.7326/0003-4819-146-4-200702200-00002.
    1. Investigators N-SS, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–1297. doi: 10.1056/NEJMoa0810625.
    1. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–1367. doi: 10.1056/NEJMoa011300.
    1. Siegelaar SE, Devries JH, Hoekstra JB. Patients with diabetes in the intensive care unit; not served by treatment, yet protected? Crit Care. 2010;14(2):126. doi: 10.1186/cc8881.
    1. Ley SCFR, Bossenroth E, Schlack WS, Preckel B. Datenlage zur perioperativen Diabetesbetreuung in einem universitatsklinikum. Diabetologe. 2008;4:13–19. doi: 10.1007/s11428-007-0187-2.
    1. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery) Diabetes Care. 2011;34(2):256–261. doi: 10.2337/dc10-1407.
    1. Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med. 2004;32(3):848–851. doi: 10.1097/01.CCM.0000114811.60629.B5.
    1. Wengritzky R, Mettho T, Myles PS, Burke J, Kakos A. Development and validation of a postoperative nausea and vomiting intensity scale. Br J Anaesth. 2010;104(2):158–166. doi: 10.1093/bja/aep370.
    1. Abdelmalak B, Maheshwari A, Mascha E, Srivastava S, Marks T, Tang WW, Kurz A, Sessler DI. Design and organization of the Dexamethasone, light anesthesia and tight glucose control (DeLiT) trial: a factorial trial evaluating the effects of corticosteroids, glucose control, and depth-of-anesthesia on perioperative inflammation and morbidity from major non-cardiac surgery. BMC Anesthesiol. 2010;10:11. doi: 10.1186/1471-2253-10-11.
    1. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi: 10.1016/j.ajic.2008.03.002.
    1. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med. 2010;38(3):838–842. doi: 10.1097/CCM.0b013e3181cc4be9.
    1. Thomas DJ, Platt HS, Alberti KG. Insulin-dependent diabetes during the peri-operative period. An assessment of continuous glucose-insulin-potassium infusion, and traditional treatment. Anaesthesia. 1984;39(7):629–637. doi: 10.1111/j.1365-2044.1984.tb06469.x.
    1. Ljungqvist O, Nygren J, Soop M, Thorell A. Metabolic perioperative management: novel concepts. Curr Opin Crit Care. 2005;11(4):295–299. doi: 10.1097/01.ccx.0000166395.65764.71.
    1. Hemmerling TM, Schmid MC, Schmidt J, Kern S, Jacobi KE. Comparison of a continuous glucose-insulin-potassium infusion versus intermittent bolus application of insulin on perioperative glucose control and hormone status in insulin-treated type 2 diabetics. J Clin Anesth. 2001;13(4):293–300. doi: 10.1016/S0952-8180(01)00276-8.
    1. Raucoules Aime M, Labib Y, Levraut J, Gastaud P, Dolisi C, Grimaud D. Use of i.v. insulin in well-controlled non-insulin-dependent diabetics undergoing major surgery. Br J Anaesth. 1996;76(2):198–202. doi: 10.1093/bja/76.2.198.
    1. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care. 2013;36(7):2118–2125. doi: 10.2337/dc12-2713.
    1. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care. 2013;36(7):2126–2132. doi: 10.2337/dc12-2504.
    1. Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366. doi: 10.1136/bmj.g2366.
    1. Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348:g2780. doi: 10.1136/bmj.g2780.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera